Skip to main content
Fig. 1 | Biomarker Research

Fig. 1

From: Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors

Fig. 1

Association of mIHC-defined immune cells with survival benefit of tislelizumab treatment A–B Kaplan–Meier overall survival analysis in subgroups defined by density of CD8+ T cells (A) and CD68+ Mφ (B) in mIHC BEP. C Representative mIHC image for four subgroups defined by density of CD8+ T cells and CD68+ Mφ. Scale bar: 50 µm. D Kaplan–Meier overall survival analysis in four subgroups defined by density of CD8+ T cells and CD68+ Mφ. Median overall survival was estimated by the Kaplan–Meier method and the log-rank test was used to compare survival curves between defined biomarker subgroups. BEP, biomarker-evaluable population; CI, confidence interval; DAPI, 4’,6-diamidino-2-phenylindole; Mφ, macrophages; mIHC, multiplex immunohistochemistry; NA, not available; Pan-CK, pan-cytokeratin

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us